Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
New Age Exploration secures $227,500 investment from Kairos Minerals

2018-07-04 proactiveinvestors.com.au
New Age Exploration Ltd (ASX:NAE) has secured an investment of $227,500 from Kairos Minerals Ltd (ASX:KAI) via the issue of 35 million shares at 0.65 cents per share.
MPJFF NAE CORC

0
New Age Exploration drilling to demonstrate 'Redmoor is a truly world-class deposit'

2018-06-29 proactiveinvestors.com.au
New Age Exploration Limited (ASX:NAE) managing director Gary Fietz provides Proactive Investors with updates on the company's recent capital raising, drilling at the flagship Redmoor Tin-Tungsten Project, and talks over the Lochinvar Coking Coal Project.
SMC SMCDY SMCDF SML NAE CORC

0
New Age Exploration raises capital to advance drilling at Redmoor Tin-Tungsten Project

2018-06-26 proactiveinvestors.com.au
New Age Exploration Ltd (ASX:NAE) has completed tranche 1 of its $1.6 million placement, raising $728,000 via the issue of shares at 0.65 cents per share.
SMC SMCDY SMCDF SML NAE CORC

0
New Age Exploration secures funding for tin tungsten project

2018-06-19 proactiveinvestors.com.au
New Age Exploration Ltd (ASX:NAE) has secured $1.6 million in commitments for a two-tranche share placement priced at 0.65 cents per share.
NAE

0
New Age Exploration tips off market to material capital raising

2018-06-15 proactiveinvestors.com.au
New Age Exploration Ltd (ASX:NAE) has been granted a trading halt by the ASX ahead of a material capital raising.
NAE

0
NAE 'chomping at the bit' to drill 'sweet spot' and update Redmoor resource

2018-05-30 proactiveinvestors.com.au
New Age Exploration Limited (ASX:NAE) managing director Gary Fietz speaks to Proactive Investors about progress with its flagship Redmoor Tin-Tungsten Project in Cornwall, UK.
NAE

0
New Age Exploration to recommence drilling to expand high-grade tin-tungsten resource

2018-05-27 proactiveinvestors.com.au
New Age Exploration Ltd (ASX:NAE) expects to commence drilling next month at its 50% owned Redmoor Tin-Tungsten Project in Cornwall, UK.
SMC SMCDY SMCDF SML NAE

0
New Age Exploration upgrades tin-tungsten resource and demonstrates coking coal viability

2018-05-11 proactiveinvestors.com.au
New Age Exploration Limited (ASX:NAE) is a diversified mining group with an advanced tin-tungsten project, a potentially large coking coal project and a gold project.
NAE CORC

0
New Age Exploration plans new drilling to extend and upgrade tin-tungsten resource

2018-04-30 proactiveinvestors.com.au
New Age Exploration Limited (ASX:NAE) is preparing for a phased drilling program aimed at expanding and upgrading the inferred mineral resource at Redmoor Tin-Tungsten Project in the UK.
NAE CORC

0
New Age Exploration just scratching the surface of Redmoor resource

2018-03-21 proactiveinvestors.com.au
Gary Fietz, Managing Director of New Age Exploration Limited (ASX:NAE) speaks to Proactive Investors' Danielle Doporto about an updated inferred mineral resource estimate and exploration target for its Redmoor Tin-Tungsten-Copper Project in the UK.
NAE

0
New Age Exploration's updated Redmoor resource features robust tin equivalent grade

2018-03-19 proactiveinvestors.com.au
New Age Exploration Limited (ASX:NAE) has released an updated inferred mineral resource estimate and exploration target for its Redmoor Tin-Tungsten Project in the UK.
NAE CORC

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to ASX:NAE / NEW AGE EXPLORATION LIMITED on message board site Silicon Investor.

Orbite Aluminae Genaera Corp
Genaera Pharmaceuticals - antibiotics, cancer, asthma